Document is current
Any future updates will be listed below
-
Authors
Stephenson, Michael J. https://orcid.org/0000-0002-2594-1806
Owen, Charlotte https://orcid.org/0000-0001-9023-2179
Reed, James https://orcid.org/0000-0001-5780-6134
Osbourn, Anne https://orcid.org/0000-0003-2195-5810
-
Funding
Funding for this research was provided by:
RCUK | Biotechnology and Biological Sciences Research Council (BB/L014130/1)
RCUK | Biotechnology and Biological Sciences Research Council (BB/S016023/1)
RCUK | Biotechnology and Biological Sciences Research Council (BB/X01097X/1)
RCUK | Biotechnology and Biological Sciences Research Council (BB/L014130/1)
RCUK | Biotechnology and Biological Sciences Research Council (BB/S016023/1)
Novo Nordisk Fonden (NNF23SA0084012)
Wellcome Trust (227375/Z/23/Z)
John Innes Foundation (-)
John Innes Foundation (-)
U.S. Department of Health & Human Services | National Institutes of Health (1R01AT010593-01)
U.S. Department of Health & Human Services | National Institutes of Health (1R01AT010593-01)
- License Information
-
More Information
Article History
Received: 5 November 2024
Accepted: 3 September 2025
First Online: 6 October 2025
Competing interests
: A.O. and J.R. are a cofounders and shareholders of HotHouse Therapeutics. A.O. serves as a consultant for this company. The remaining authors declare no competing interests.
